ENTEREG reduced time to GI recovery by up to 1 day1,2


Mean time to GI recovery

  • Data are from 5 multicenter, randomized, double-blind, placebo-controlled studies in patients undergoing bowel resection with primary anastomosis. Patients were administered ENTEREG 12 mg or placebo 30 minutes to 5 hours prior to surgery and twice daily after surgery until hospital discharge, for a maximum of 7 days
  • Patients who received more than 3 doses of an opioid (regardless of route) during the 7 days prior to surgery and patients with complete bowel obstruction or who were scheduled for a total colectomy, colostomy, or ileostomy were excluded
  • Studies 1 and 2 contained the largest number of bowel resection patients in the US
  • Study 5 was a non-US study—the use of nonopioid analgesics was substantially higher as compared with the US studies for both treatment groups

Patients in all clinical study arms were placed on a standardized accelerated postoperative care pathway, including1:

  • Removal of NG tube before first postoperative dose
  • Early ambulation
  • Early feeding

ENTEREG reduced time to discharge order written (DOW)1,2

Mean improvement in time to DOW

NEXT: Important Safety Information and Dosing

Prescribing Information including Boxed Warning

Important Safety Information

WARNING: FOR SHORT-TERM HOSPITAL USE ONLY
ENTEREG is available only for short-term (15 doses) use in hospitalized patients.
Only hospitals that have registered in and met all of the requirements for the
ENTEREG Access Support & Education (E.A.S.E.™) Program may use ENTEREG.
  • ENTEREG is contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking ENTEREG
  • There were more reports of myocardial infarctions in patients treated with alvimopan 0.5 mg twice daily compared with placebo-treated patients in a 12-month study of patients treated with opioids for chronic pain. In this study, the majority of myocardial infarctions occurred between 1 and 4 months after initiation of treatment. This imbalance has not been observed in other studies of alvimopan, including studies of patients undergoing bowel resection surgery who received alvimopan 12 mg twice daily for up to 7 days. A causal relationship with alvimopan has not been established
  • ENTEREG should be administered with caution to patients receiving more than 3 doses of an opioid within the week prior to surgery. These patients may be more sensitive to ENTEREG and may experience GI side effects (eg, abdominal pain, nausea and vomiting, diarrhea)
  • ENTEREG is not recommended for use in patients with severe hepatic impairment, end-stage renal disease, or in patients undergoing surgery for correction of complete bowel obstruction
  • ENTEREG is available only to hospitals that enroll in the E.A.S.E. Program. To enroll in the E.A.S.E. Program, the hospital must acknowledge that:
    • Hospital staff who prescribe, dispense, or administer ENTEREG have been provided the educational materials on the need to limit use of ENTEREG to short-term, inpatient use
    • Patients will not receive more than 15 doses of ENTEREG
    • ENTEREG will not be dispensed to patients after they have been discharged from the hospital

Adverse event reporting

Healthcare professionals should report all suspected adverse events associated with the use of ENTEREG. Please contact Adolor Corporation at 700 Pennsylvania Drive, Exton, PA 19341 or
1-866-4ADOLOR (1-866-423-6567).

Alternatively, this information may be reported to the FDA MedWatch Reporting System by phone at 1-800-FDA-1088 (1-800-332-1088) or by mail using Form 3500 at www.fda.gov/medwatch.

If you have any questions, please contact Adolor Corporation at 1-866-4ADOLOR (1-866-423-6567).